HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Epshteyn, V. Articles by Maisel, A. Search for Related Content PubMed PubMed Citation Articles by Epshteyn, V. Articles by Maisel, A. Social Bookmarking                What's this?

Utility of B-Type Natriuretic Peptide (BNP) as a Screen for Left Ventricular Dysfunction in Patients With Diabetes

¹ Department of Medicine, Veteran’s Affairs Medical Center, San Diego, California
² Biosite Diagnostics, San Diego, California
³ University of California, San Diego, California

Address correspondence and reprint requests to Robert R. Henry, MD, VA San Diego Healthcare System (Mail Code 111G), 3350 La Jolla Village Dr., San Diego, CA 92161. E-mail: rrhenry{at}vapop.ucsd.edu.

OBJECTIVE—Routine screening of diabetic patients with echocardiography is not feasible due to its limited availability and high cost. B-type natriuretic peptide (BNP) is secreted from the left ventricle in response to pressure overload and is elevated in both systolic and diastolic dysfunction.

RESEARCH DESIGN AND METHODS—BNP levels were compared to echocardiographic findings in 263 patients. Patients were divided into two groups: clinical indication for echocardiography (CIE) (n = 172) and those without clinical indication for echocardiography (no-CIE) (n = 91). Cardiologists making the assessment of left ventricular function were blinded when measuring plasma levels of BNP.

RESULTS—The 91 patients with no-CIE with echos had similar BNP levels (83 ± 16 pg/ml) to the 215 patients with no-CIE without echos (63 ± 10, P = 0.10). Patients with CIE and subsequent abnormal left ventricular function (n = 112) had a mean BNP concentration of 435 ± 41 pg/ml, compared with those with no-CIE, but had abnormal left ventricular function on echo (n = 32) (161 ± 40 pg/ml). Twenty-one of 32 patients with no-CIE but with abnormal left ventricular function had diastolic dysfunction (BNP 190 ± 60pg/ml). A receiver-operating characteristic (ROC) curve revealed that the area under the curve was 0.91 for CIE patients and 0.81 for no-CIE patients (P < 0.001). For those with no congestive heart failure (CHF) symptoms, BNP levels showed a high negative predictive value (91% for BNP values <39 pg/ml), while in those patients who had a CIE, BNP levels showed a high positive predictive value for the detection of left ventricular dysfunction (96% with BNP levels >90 pg/ml).

CONCLUSIONS—BNP can reliably screen diabetic patients for the presence or absence of left ventricular dysfunction.

Abbreviations: AUC, area under the curve • BNP, B-type natriuretic peptide • CHF, congestive heart failure • CIE, clinical indication for echocardiography • IVRT, isovolumetric relaxation time • no-CIE, no clinical indication for echocardiography • NYHA, New York Heart Association • ROC, receiver-operating characteristic

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]

				P. Symeonides, S. Koulouris, E. Vratsista, K. Triantafyllou, G. Ioannidis, N. Thalassinos, and D. Katritsis Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: A comparative study Eur J Echocardiogr, December 1, 2007; 8(6): 480 - 486. [Abstract] [Full Text] [PDF]

				M. Lajer, L. Tarnow, A. Jorsal, and H.-H. Parving Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3235 - 3239. [Abstract] [Full Text] [PDF]

				W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				C. Kragelund, I. Gustafsson, T. Omland, B. Gronning, L. Kober, J. Faber, S. Strande, R. Steffensen, and P. Hildebrandt Prognostic Value of NH2-Terminal Pro B-Type Natriuretic Peptide in Patients With Diabetes and Stable Coronary Heart Disease. Diabetes Care, June 1, 2006; 29(6): 1411 - 1413. [Full Text] [PDF]

				R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208. [Abstract] [Full Text] [PDF]

				R. Valle, E. Bagolin, C. Canali, P. Giovinazzo, S. Barro, N. Aspromonte, E. Carbonieri, and L. Milani The BNP assay does not identify mild left ventricular diastolic dysfunction in asymptomatic diabetic patients Eur J Echocardiogr, January 1, 2006; 7(1): 40 - 44. [Abstract] [Full Text] [PDF]

				L. Chung, A. Georges, J. B. Corcuff, L. Bordenave, H. Gin, and V. Rigalleau B-Type Natriuretic Peptide in Type 2 Diabetes: The influence of chronic renal failure and food Diabetes Care, March 1, 2005; 28(3): 752 - 752. [Full Text] [PDF]

				A. H.B. Wu, T. Omland, P. Duc, J. McCord, R. M. Nowak, J. E. Hollander, H. C. Herrmann, P. G. Steg, C. Wold Knudsen, A. B. Storrow, et al. The Effect of Diabetes on B-Type Natriuretic Peptide Concentrations in Patients With Acute Dyspnea: An analysis from the Breathing Not Properly Multinational Study Diabetes Care, October 1, 2004; 27(10): 2398 - 2404. [Abstract] [Full Text] [PDF]

				M. A. Bhalla, A. Chiang, V. A. Epshteyn, R. Kazanegra, V. Bhalla, P. Clopton, P. Krishnaswamy, L.K. Morrison, A. Chiu, N. Gardetto, et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus J. Am. Coll. Cardiol., September 1, 2004; 44(5): 1047 - 1052. [Abstract] [Full Text] [PDF]

				D. Liew, H. Schneider, J. D'Agostino, J. Shaw, and H. Krum Utility of B-Type Natriuretic Peptide as a Screen for Left Ventricular Dysfunction in Patients With Diabetes: Response to Epshteyn et al. Diabetes Care, March 1, 2004; 27(3): 848 - 848. [Full Text] [PDF]

				R. R. Henry and A. Maisel Utility of B-Type Natriuretic Peptide as a Screen for Left Ventricular Dysfunction in Patients With Diabetes: Response to Liew et al. Diabetes Care, March 1, 2004; 27(3): 848 - 849. [Full Text] [PDF]